Leave message
Can’t find what you’re looking for?
Fill out this form to inquire about our custom protein services!
Inquire about our Custom Services >>
Limited Edition Golden Llama is here! Check out how you can get one. Limited Edition Golden Llama is here! Check out how you can get one.
Offering SPR-BLI Services - Proteins provided for free!Get your ComboX free sample to test now!
Time Limited Offer: Welcome Gift for New Customers ! Shipping Price Reduction for EU Regions
This protein carries a polyhistidine tag at the C-terminus.
The protein has a calculated MW of 25.2 kDa. The protein migrates as 35-45 kDa under reducing (R) condition (SDS-PAGE) due to glycosylation.
>95% as determined by SDS-PAGE.
>90% as determined by SEC-MALS.
Lyophilized from 0.22 μm filtered solution in PBS, pH7.4 with trehalose as protectant.
Contact us for customized product form or formulation.
Please see Certificate of Analysis for specific instructions.
For best performance, we strongly recommend you to follow the reconstitution protocol provided in the CoA.
For long term storage, the product should be stored at lyophilized state at -20°C or lower.
Please avoid repeated freeze-thaw cycles.
This product is stable after storage at:
Human B7-H3 Protein, His Tag on SDS-PAGE under reducing (R) condition. The gel was stained with Coomassie Blue. The purity of the protein is greater than 95%.
The purity of Human B7-H3 Protein, His Tag (Cat. No. B73-H52E2) is more than 90% and the molecular weight of this protein is around 30-40 kDa verified by SEC-MALS.
Immobilized Human B7-H3, His Tag (Cat. No. B73-H52E2) at 2 μg/mL (100 μL/well) can bind Monoclonal Anti-Human B7-H3 / B7-H3 (4Ig) Antibody, Human IgG1 with a linear range of 0.3-5 ng/mL (QC tested).
Immobilized Monoclonal Anti-Human B7-H3 / B7-H3 (4Ig) Antibody, Human IgG1 at 2 μg/mL (100 μL/well) can bind Human B7-H3, His Tag (Cat. No. B73-H52E2) with a linear range of 0.01-0.156 μg/mL (Routinely tested).
Loaded Monoclonal Anti-Human B7-H3 / B7-H3 (4Ig) Antibody, Human IgG1 (Cat. No. B73-M51) on Protein A Biosensor, can bind Human B7-H3 Protein, His Tag (Cat. No. B73-H52E2) with an affinity constant of 479 nM as determined in BLI assay (ForteBio Octet Red96e) (Routinely tested).
Human B7-H3, His Tag (Cat. No. B73-H52E2) inhibits Anti-CD3-induced proliferation of PBMC. The EC50 for this effect is 2.24-3.36 μg/mL (Routinely tested).
Explore our catalog of therapeutic antibody solutions to find the right products for you! We are dedicated to delivering solutions designed to help you drive innovation and push the boundaries of what therapeutic antibodies can be.
We offer a wide range of cell and gene therapy solutions starting from discovery to the clinic. Explore our wide range of proteins, antibodies, kits, and other assays to accelerate the development of your cell and gene therapy.
Organoid Toolbox is a collection of organoid solutions including ready-to-use organoids, organoid differentiation kits, and a variety of services to accelerate the progress of your drug development project.
ACROBiosystems developed a series of GMP grade cytokines under the GMP grade quality management system. Those products are all suitable for T/NK cell generation, activation, and proliferation in cell therapy research.
50+ targets designed for CAR detection, including PE/FITC/biotin labeled proteins. The key reagents for CD19 and BCMA were FDA DMF filed which can support your IND, NDA and BLA process.
GMP grade cytokines, reagents for cell activation, gene edition, DNA/RNA removal, etc. Particularly focus on product design, quality control and solution-based support to link each phase of your cell and gene therapy journey.
Full length multi-pass TPs with stabilized structure and high bioactivity for immunization, antibody screening, cell based assay and CAR detection, including hot CD20, Claudin 18.2, CD133, GPRC5D,CCR8, CCR5, etc.
A series of immune checkpoints including classic co-inhibitory and co-stimulatory receptors. The comprehensive catalog contains 100+ targets with various species and tags, and the high-quality proteins are in good batch-to-batch consistency.
To meet the needs of ADCs development, ACROBiosystems can provide: A variety of high-quality target proteins; MMPs/Cathepsin/uPA for cleavable linker; Anti-payload antibodies & anti-idiotypic antibodies for immunogenicity and PK analysis; SPR/BLI analytical and ADA development service.
Comprehensive collection of Fc receptor proteins, including their common variants, which can help expedite your antibody development.
Comprehensive cytokine targets including interleukins, growth factors, chemokines, TNFs, etc. are expressed by HEK293 to ensure their natural structure. Their high purity is verified by SDS-PAGE/HPLC/SEC-MALS and high bioactivity is verified by ELISA/SPR/BLI.
Aneuro provides innovative solutions for neuroscience research. Recombinant proteins, neural factors, pre-formed fibrils, electrophysiological electrodes, as well as Organoid Toolbox all in Aneuro aiming to advance neuroscience research, develop therapeutic interventions, and improve diagnostic methods for neurological diseases.
English Name | Research Code | Research Phase | Company | First Brand Name | First Approved Country | First Indication | First Approved Company | First Approved Fecha | Indications | Clinical Trials |
---|
English Name | Research Code | Research Phase | Company | Indications | Clinical Trials |
---|---|---|---|---|---|
Ifinatamab deruxtecan | DS-7300; DS-7300a; MABX-9001a | Phase 3 Clinical | Daiichi Sankyo Co Ltd | Solid tumours; Small Cell Lung Carcinoma | Details |
B7-H3 CAR-T cell therapy (Boyuan Runsheng Pharma) | Phase 2 Clinical | Boyuan Runsheng Pharma (Hangzhou) Co Ltd | Solid tumours; Glioblastoma | Details | |
Obrindatamab | MGD-009; B7-H3 x CD3 | Phase 2 Clinical | Macrogenics Inc | Mesothelioma; Carcinoma, Non-Small-Cell Lung; Melanoma; Thyroid Neoplasms; Sarcoma; Neuroblastoma; Neurofibrosarcoma; Prostatic Neoplasms; Breast Neoplasms; Ovarian Neoplasms; Sarcoma, Synovial; Urinary Bladder Neoplasms; Wilms Tumor; Pancreatic Neoplasms; Colonic Neoplasms; Carcinoma, Renal Cell; Squamous Cell Carcinoma of Head and Neck; Rhabdomyosarcoma | Details |
Vobramitamab duocarmazine | MGC-018 | Phase 2 Clinical | Macrogenics Inc | Liver Neoplasms; Solid tumours; Squamous Cell Carcinoma of Head and Neck; Anus Neoplasms; Carcinoma, Renal Cell; Small Cell Lung Carcinoma; Carcinoma, Ovarian Epithelial; Prostatic Neoplasms, Castration-Resistant; Prostatic Neoplasms; Laryngeal Neoplasms; Carcinoma, Squamous Cell; Carcinoma, Small Cell; Carcinoma, Pancreatic Ductal; Carcinoma, Non-Small-Cell Lung; Melanoma | Details |
TAK-280 | MVC-280; TAK-280 | Phase 2 Clinical | Maverick Therapeutics Inc | Solid tumours; Neoplasms; Neoplasm Metastasis | Details |
4SCAR-276 | 4SCAR-276 | Phase 2 Clinical | Shenzhen Geno-Immune Medical Institute | Solid tumours | Details |
IBI-3001 | IBI-3001; IBI3001 | Phase 2 Clinical | Innovent Biologics(Suzhou) Co Ltd | Solid tumours | Details |
Allogenic B7H3-targeting CAR-γδT Cell Therapy | QH104 Cell; QH-104 Cell | Phase 2 Clinical | Suzhou Dushu Lake Hospital (Dushu Lake Hospital Affiliated To Soochow University) | Glioblastoma | Details |
IBI129 | IBI-129; IBI129 | Phase 2 Clinical | Innovent Biologics(Suzhou) Co Ltd | Solid tumours | Details |
7MW3711 | 7-MW-3711; 7MW3711 | Phase 2 Clinical | Mabwell (Shanghai) Bioscience Co Ltd | Solid tumours; Neoplasms | Details |
IBI334 | IBI334; IBI-334 | Phase 2 Clinical | Innovent Biologics(Suzhou) Co Ltd | Solid tumours; Neoplasms | Details |
MHB088C | MHB-088C | Phase 2 Clinical | Minghui Pharmaceutical Pty Ltd | Solid tumours | Details |
DB-1311 | DB-1311 | Phase 2 Clinical | Duality Biologics Co Ltd | Solid tumours; Neoplasm Metastasis | Details |
IBB-0979 | IBB0979; IBB-0979 | Phase 2 Clinical | SunHo (China) BioPharmaceutical Co Ltd | Solid tumours; Neoplasms | Details |
YL-201 | YL-201; YL201 | Phase 2 Clinical | MediLink Therapeutics Co Ltd | Solid tumours; Prostatic Neoplasms, Castration-Resistant | Details |
Fully Human B7H3 CAR-T Cells Therapy | fhB7H3.CAR-Ts | Phase 2 Clinical | The Affiliated Hospital Of Xuzhou Medical University | Ovarian Neoplasms; Carcinoma, Hepatocellular | Details |
CD-276-targeted Chimeric Antigen Receptor T Cell Therapy | CD276 CAR-T | Phase 2 Clinical | Shenzhen University General Hospital | Pancreatic Neoplasms | Details |
Enoblituzumab | MGA-271; TJ271 | Phase 2 Clinical | Macrogenics Inc | Carcinoma, Transitional Cell; Melanoma; Carcinoma, Non-Small-Cell Lung; Fallopian Tube Neoplasms; Peritoneal Neoplasms; Osteosarcoma; Neuroblastoma; Sarcoma, Ewing; Prostatic Neoplasms; Urethral Neoplasms; Urinary Bladder Neoplasms; Ovarian Neoplasms; Neoplasms; Triple Negative Breast Neoplasms; Wilms Tumor; Carcinoma, Renal Cell; Desmoplastic Small Round Cell Tumor; Abdominal Neoplasms; Squamous Cell Carcinoma of Head and Neck; Solid tumours; Rhabdomyosarcoma; Head and Neck Neoplasms | Details |
HS-20093 | HS20093; HS-20093 | Phase 2 Clinical | Shanghai Hansoh Biomedical Co Ltd | Solid tumours; Squamous Cell Carcinoma of Head and Neck; Esophageal Neoplasms; Small Cell Lung Carcinoma; Prostatic Neoplasms, Castration-Resistant; Sarcoma; Osteosarcoma | Details |
124I-omburtamab | 124I-8H9; 124I-8H9-(B7-H3) | Phase 1 Clinical | Memorial Sloan Kettering Cancer Center, Y-Mabs Therapeutics Inc | Brain Neoplasms; Glioma | Details |
Mirzotamab clezutoclax | ABBV-155 | Phase 1 Clinical | Abbvie Inc | Solid tumours | Details |
SCRI-CARB7H3 | SCRI-CARB7H3 | Phase 1 Clinical | Seattle Children'S Hospital | Neuroblastoma; Choroid Plexus Neoplasms; Neoplasms, Germ Cell and Embryonal; Melanoma; Glioma; Diffuse Intrinsic Pontine Glioma; Neuroectodermal Tumors, Primitive; Sarcoma; Sarcoma, Clear Cell; Neurofibrosarcoma; Sarcoma, Ewing; Osteosarcoma; Retinoblastoma; Teratoma; Sarcoma, Synovial; Central Nervous System Neoplasms; Wilms Tumor; Diffuse midline glioma; Hepatoblastoma; Rhabdoid Tumor; Desmoplastic Small Round Cell Tumor; Carcinoma; Rhabdomyosarcoma; Medulloblastoma; Solid tumours; Ependymoma | Details |
CC-3 | CC-3 | Phase 1 Clinical | Eberhard Karls University Of Tubingen, Germany | Colorectal Neoplasms; Gastrointestinal Neoplasms | Details |
KT-095 | KT-095 | Phase 1 Clinical | Nanjing Kati Medical Technology Co Ltd | Solid tumours | Details |
EX-105 | EX-105; EX105 | Phase 1 Clinical | Guangzhou Excelmab Inc | Solid tumours | Details |
MGC-026 | MGC026; MGC-026 | Phase 1 Clinical | Macrogenics Inc | Prostatic Neoplasms, Castration-Resistant; Uterine Cervical Neoplasms; Neoplasm Metastasis; Carcinoma, Non-Small-Cell Lung; Carcinoma, Hepatocellular; Melanoma; Endometrial Neoplasms; Colorectal Neoplasms; Sarcoma; Urinary Bladder Neoplasms; Ovarian Neoplasms; Neoplasms; Small Cell Lung Carcinoma; Pancreatic Neoplasms; Stomach Neoplasms; Esophageal Neoplasms; Squamous Cell Carcinoma of Head and Neck; Carcinoma, Renal Cell; Solid tumours | Details |
Loco-regional B7H3 IL-7Ra CAR T Cell therapy(Chulalongkorn University) | Phase 1 Clinical | Chulalongkorn University, King Chulalongkorn Memorial Hospital | Brain Neoplasms; Diffuse Intrinsic Pontine Glioma | Details | |
Autologous CAR-T Cells Targeting B7-H3(Unc Lineberger Comprehensive Cancer Center) | Phase 1 Clinical | Unc Lineberger Comprehensive Cancer Center | Ovarian Neoplasms; Pancreatic Neoplasms; Carcinoma, Ovarian Epithelial; Triple Negative Breast Neoplasms; Neoplasms; Breast Neoplasms | Details | |
MT-027 | MT-027 | Phase 1 Clinical | T-Maximum Pharmaceutical (Suzhou) Co Ltd | Glioma | Details |
UTAA06 | UTAA-06 | Phase 1 Clinical | Persongen Biotherapeutics (Suzhou) Co Ltd | Leukemia, Myeloid, Acute | Details |
B7-H3 CAR T-cell therapy(Stanford University) | B7-H3CART | Phase 1 Clinical | Stanford University | Nervous System Diseases | Details |
TX103 CAR-T cell therapy(Fuzhou Tuoxin Tiancheng Biotechnology) | Phase 1 Clinical | Fuzhou Tuoxin Tiancheng Biotechnology Co Ltd | Solid tumours; Glioma | Details | |
EGFR/B7H3 CAR-T | EGFR/B7H3 CAR-T | Phase 1 Clinical | Second Affiliated Hospital Of Guangzhou Medical University | Triple Negative Breast Neoplasms; Lung Neoplasms | Details |
BAT-8009 | BAT8009; BAT-8009 | Phase 1 Clinical | Bio-Thera Solutions Ltd | Solid tumours | Details |
TAA-06 | TAA06-UCAR-γδT; TAA-06 | Phase 1 Clinical | Persongen Biotherapeutics (Suzhou) Co Ltd | Solid tumours; Neuroblastoma; Colorectal Neoplasms; Lung Neoplasms; Melanoma | Details |
XmAb-808 | XmAb808 | Phase 1 Clinical | Xencor Inc | Carcinoma, Renal Cell; Squamous Cell Carcinoma of Head and Neck; Carcinoma, Transitional Cell; Carcinoma, Ovarian Epithelial; Triple Negative Breast Neoplasms; Prostatic Neoplasms, Castration-Resistant; Colorectal Neoplasms; Melanoma; Carcinoma, Non-Small-Cell Lung | Details |
Anti-CD276 CAR T-cell therapy (Persongen ) | Phase 1 Clinical | Persongen Biotherapeutics (Suzhou) Co Ltd | Stomach Neoplasms; Small Cell Lung Carcinoma; Osteosarcoma; Neuroblastoma; Lung Neoplasms | Details | |
B7-H3-targeting CAR-T cell therapy | Beijing Tiantan Hospital, Capital Medical University | Details |
This web search service is supported by Google Inc.